NASDAQ:KYMR

Kymera Therapeutics Price Target, Predictions & Analyst Ratings

$62.95
-1.95 (-3.00 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$58.20
$64.20
50-Day Range
$47.80
$66.66
52-Week Range
$27.65
$91.92
Volume2.17 million shs
Average Volume319,437 shs
Market Capitalization$3.21 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Kymera Therapeutics (NASDAQ:KYMR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 6 Analyst Ratings

Analyst Price Target Consensus

$76.00

High PT$80.00
Average PT$76.00
Low PT$68.00
TypeCurrent
9/19/20 to 9/19/21
1 Month Ago
8/20/20 to 8/20/21
3 Months Ago
6/21/20 to 6/21/21
1 Year Ago
9/20/19 to 9/19/20
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$76.00$56.25$56.00$34.67
Price Target Upside20.73% Upside31.59% Upside38.55% Upside5.76% Upside
Get Kymera Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kymera Therapeutics (NASDAQ:KYMR) vs. Its Competitors

TypeKymera TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.73
2.56
Consensus RatingBuyBuyBuy
Price Target Upside122.77% Upside8.38% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
10
43.48%
Underperform Votes
13
56.52%
Avg. Outperform Votes
178
67.17%
Avg. Underperform Votes
87
32.83%
Avg. Outperform Votes
829
69.55%
Avg. Underperform Votes
363
30.45%

Kymera Therapeutics (NASDAQ:KYMR) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/10/2021Bank of America
DowngradeBuy ➝ Neutral$65.00 ➝ $80.00+24.67%
8/18/2021Morgan Stanley
Lower Price TargetEqual Weight$69.00 ➝ $68.00+30.39%
5/20/2021UBS Group
Initiated CoverageBuy$80.00+84.71%
4/14/2021Berenberg Bank
Initiated CoverageBuy
12/4/2020HC Wainwright
A. Fein
Initiated CoverageBuy
11/13/2020Piper Sandler
Initiated CoverageOverweight
9/15/2020Guggenheim
Initiated CoverageBuy$42.00+420,000,000.00%
9/15/2020Cowen
Initiated CoverageOutperform
(Data available from 9/19/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)
speech bubbles
speech bubbles











Kymera Therapeutics (NASDAQ:KYMR) Analyst Ratings Frequently Asked Questions

What is Kymera Therapeutics's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for Kymera Therapeutics stock is Buy based on the current 2 hold ratings and 4 buy ratings for KYMR. The average twelve-month price target for Kymera Therapeutics is $76.00 with a high price target of $80.00 and a low price target of $68.00. Learn more on KYMR's analyst rating history

Do Wall Street analysts like Kymera Therapeutics more than its competitors?

Analysts like Kymera Therapeutics stock less than the stock of other Medical companies. The consensus rating score for Kymera Therapeutics is 2.67 while the average consensus rating score for medical companies is 2.73. Learn more on how KYMR compares to other companies

Do MarketBeat users like Kymera Therapeutics more than its competitors?

MarketBeat users like Kymera Therapeutics stock less than the stock of other Medical companies. 43.48% of MarketBeat users gave Kymera Therapeutics an outperform vote while medical companies recieve an average of 67.17% outperform votes by MarketBeat users.

Is Kymera Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Kymera Therapeutics's stock had 1 downgrade by analysts.

Does Kymera Therapeutics's stock price have much upside?

According to analysts, Kymera Therapeutics's stock has a predicted upside of 42.83% based on their 12-month price targets.

What analysts cover Kymera Therapeutics?

Kymera Therapeutics has been rated by Bank of America, and Morgan Stanley in the past 90 days.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.